Quick Answer
MBX Biosciences, Inc. reported Stockholders Equity of $369.22 million for fiscal year 2025.
MBX Biosciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $369.22M | +43.4% |
| 2024 | $257.44M | +455.2% |
| 2023 | -$72.47M | -70.1% |
| 2022 | -$42.60M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $387.54M | +42.8% | +76.8% |
| June 30, 2025 | $219.24M | +324.0% | -6.9% |
| March 31, 2025 | $235.42M | +383.5% | -8.6% |
| December 31, 2024 | $257.44M | +455.2% | -5.1% |
| September 30, 2024 | $271.37M | +518.7% | +377.2% |
| June 30, 2024 | -$97.89M | -76.7% | -17.9% |
| March 31, 2024 | -$83.05M | -72.0% | -14.6% |
| December 31, 2023 | -$72.47M | -70.1% | -11.8% |
- MBX Biosciences, Inc. showed an increase of +43.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, MBX Biosciences, Inc.’s stockholders equity has grown by 966.6% (from -$42.60 million to $369.22 million).
- The most recent figure is from MBX Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: